Bannerbild German Brest Group

German Breast Group News

We keep you up to date with what’s going on, including the latest information about studies and events conducted by the German Breast Group.

Visit our exhibition stand!

11th Düsseldorf Breast Cancer Conference, 17 - 18 June 2016

Congress venue: CCD Stadthalle, Congress Center Düsseldorf

Exhibition stand of the German Breast Group: booth number not yet known.

Posters presented at the SABCS 2015

This year, the GBG presented 14 posters at the San Antonio Breast Cancer Congress.

A list of the posters is shown in the publications section of this website.

Research group launches collaborative project “TransLUMINAL-B”

Breast cancer: more accurate diagnosis and more targeted therapy

17 November 2015

Under the leadership of the Charité University Hospital in Berlin, a kick-off meeting has marked the start of the research project “TransLUMINAL-B”. Over the next three years, research will be carried out into the process of metastasis formation and the role of malignant cells which accumulate in the blood and bone marrow in patients with certain types of breast cancer. German Cancer Aid (Deutsche Krebshilfe) is sponsoring the project to the tune of 2 million euros as part of its “Translational Oncology“ priority programme.

In Germany, 72,000 women develop breast cancer every year. The current research project will be addressing the most common form of the disease, the so-called luminal tumours. These tumours account for 70 to 80 per cent of breast cancer cases and are characterised by the fact that their growth is hormone-dependent. They are therefore generally treated by means of endocrine, i.e. hormone therapy. This is effective in many, but not all cases. One group of luminal tumours carries a high risk; these tumours are often resistant to therapy, which leads to relapses and metastases.
Initially, only a few isolated tumour cells are found in the blood and bone marrow. However, these few cells play a critical role in the spread of the tumour through the body. In order to gain a better understanding of this mechanism, Prof. Dr. Carsten Denkert, research group leader at the Charité’s Institute of Pathology, and his team will be examining changes in the individual cancer cells taken from the blood and bone marrow within the context of the TransLUMINAL-B project. Their aim is to establish why and how these cells spread through the body and why they have so far been resistant to current forms of treatment. “We intend to investigate the special characteristics of individual malignant cells from the blood and in the tumour tissue and then compare the two,“ explains Prof. Carsten Denkert. “In future this should enable us to predict, even at the initial tumour detection stage, whether the disease is likely to have a poor prognosis with a high risk of metastases.” This knowledge will enable us to treat tumours in a more targeted manner right from the start and thus win valuable time.

German Cancer Aid’s priority programme “Translational Oncology”

In 2014, German Cancer Aid set up the “Translational Oncology” priority programme with the aim of accelerating the transfer of findings from the laboratory to clinical practice. The term “translational oncology” denotes the interface between scientific research and its practical applications. Its purpose is to ensure that patients benefit promptly from laboratory findings in the form of improved diagnostic and therapy options.

Collaborative project TransLUMINAL-B

The TransLUMINAL-B project is being coordinated by Prof. Dr. Carsten Denkert from the Institute of Pathology at the Charité University Hospital in Berlin. The participating partners are the German Cancer Research Centre in Heidelberg (Prof. Dr. Andreas Trumpp), the Institute of Pathology at the University of Heidelberg (Prof. Dr. Wilko Weichert), the University of Regensburg (Prof. Dr. Gero Brockhoff and Prof. Dr. Christoph Klein) and the German Breast Group (Prof. Dr. Sibylle Loibl).


Prof. Dr. Carsten Denkert
Institut für Pathologie
Charité – Universitätsmedizin Berlin
Tel: +49 30 450 536 047
Email: crstndnkrtchrtd

AG Translationale Tumorforschung


  • 01.03.2019 Evaluation of sCAIX as predictive marker for efficacy of neoadjuvant bevacizumab

    A translational research study performed with samples obtained from a cohort of patients with HER2-negative breast cancer enrolled in the neoadjuvant GeparQuinto (GBG 44) trial has been published in the International Journey of Cancer.

    Mehr ...
  • 04.02.2019 ESMO Breast Cancer 2019

    ESMO Breast Cancer 2019

    ESMO Breast Cancer is an annual congress taking place on 2-4 May 2019 in Berlin, Germany.

    Mehr ...
  • 01.02.2019 Results of the GeparOcto trial

    We are delighted to inform you that the results of the GeparOcto phase III study designed to compare a sequential dose-dense, dose-intensified (idd) ETC (epirubicin, paclitaxel, cyclophosphamide) with weekly PM(Cb) (paclitaxel, liposomal doxorubicin, carboplatin) for neoadjuvant treatment of patients with high-risk early breast cancer have been published in the European Journal of Cancer.

    Mehr ...
  • 18.01.2019 Prof. Loibl among highly cited researchers 2018

    Prof. Dr. Sibylle Loibl, CEO of the GBG Forschungs GmbH and Professor at the Goethe University Frankfurt is featured among these researchers in 2018 for her work in breast cancer research.

    Mehr ...
  • 17.12.2018 Results of an interim analysis from KATHERINE trial

    We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd